Lelipel 4 mg 14 sachets

Tradename

Lelipel

Compound:

Each sachet contains:

Montelukast sodium 4.2 mg, equivalent to montelukast 4 mg

Auxiliary components:

Mannitol, hydroxypropyl cellulose, magnesium stearate.

Properties

Leukotriene receptor antagonist. Montelukast binds with high selectivity and chemical affinity to CysLT1 receptors (instead of other pharmacologically important airway receptors such as prostaglandin, cholinergic or β-adrenergic receptors).

Montelukast inhibits the physiological action of the cisgeinyl leukotrienes LTC4, LTD4 and LTE4 by binding to the CysLT1 receptors without stimulating these receptors. Montelukast inhibits CysLT1 receptors in the epithelium of the respiratory tract, thus simultaneously possessing the ability to inhibit bronchospasm caused by inhalation of LTD4 in patients with bronchial asthma.

Montelukast causes bronchodilation within 2 hours of oral administration and may supplement bronchodilation induced by beta2-agonists.

Indications

Prevention and long-term treatment of bronchial asthma, including: prevention of day and night symptoms of the disease; treatment of bronchial asthma in patients with hypersensitivity to acetylsalicylic acid; prevention of exercise-induced bronchospasm.

Relief of daytime and nighttime symptoms of seasonal allergic rhinitis.

Dosage and administration

Montelukast is taken by mouth.

Children from 2 to 5 years old take 4 mg (1 sachet) per day.

Children from 6 months to 2 years of age to relieve asthma take 1 sachet of 4 mg once a day.

Contraindications

Hypersensitivity to montelukast; children’s age — depending on the dosage form.

Precautionary measures:

The efficacy of oral montelukast in the treatment of acute asthma attacks has not been established. Therefore, oral montelukast is not recommended for the treatment of acute asthma attacks. Patients should be instructed to carry emergency asthma medications (short-acting inhaled beta2-agonists) with them at all times.

Side effects

Infectious diseases: very often — infections of the upper respiratory tract.

From the nervous system: infrequently — headache, dizziness, drowsiness, paresthesia / hypoesthesia, convulsions.

From the side of the cardiovascular system: rarely — palpitations.